1. Field of the Invention
The present invention relates generally to the field of surgical tissue removal, and more specifically to ultrasonic power delivery during surgical tissue removal procedures such as phacoemulsification.
2. Description of the Related Art
Phacoemulsification surgery has been successfully employed in the treatment of certain ocular problems, such as cataracts. Phacoemulsification surgery utilizes a small corneal incision to insert the tip of at least one phacoemulsification handheld surgical implement, or handpiece. The handpiece includes a needle that is ultrasonically driven once placed within an incision to emulsify the eye lens, or break the cataract into small pieces. The broken cataract pieces may subsequently be removed using the same handpiece or another handpiece in a controlled manner. The surgeon may then insert lens implants in the eye through the incision. The incision is allowed to heal, and the results for the patient are typically significantly improved eyesight.
As may be appreciated, the flow of fluid to and from a patient through a fluid infusion or extraction system and power control of the phacoemulsification handpiece is critical to the procedure performed. Different medically recognized techniques have been utilized for the lens removal portion of the surgery. Among these, one popular technique is a simultaneous combination of phacoemulsification, irrigation and aspiration using a single handpiece. This method includes making the incision, inserting the handheld surgical implement to emulsify the cataract or eye lens. Simultaneously with this emulsification, the handpiece provides a fluid for irrigation of the emulsified lens and a vacuum for aspiration of the emulsified lens and inserted fluids.
Pulse delivery has developed from a simple on/off arrangement through what is known as a burst delivery or pulse delivery, using fixed off periods or fixed duty cycles, to a specific pulse delivery such as the Whitestar pulse delivery method of Advanced Medical Optics Corporation of Santa Ana, Calif. Such designs provide the surgeon with different functionality useful in different phacoemulsification procedures, such as breaking the lens or removing the lens.
Previous systems have employed either an optimum phase angle to affect constant energy transfer into the tissue or apply a modulated voltage amplitude shaping pulse to control the phacoemulsification handpiece. These procedures can produce a significant amount of heat in the affected area. Care must be taken to avoid overheating of eye tissue during phacoemulsification while still performing the desired cutting or removal procedures. The risk of damaging the affected area via application of heat can be a considerable negative side effect.
Conditions may arise during ocular surgeries that reduce the cutting effectiveness of current pulse shaping designs. In particular, one undesirable effect exhibited by these systems is that small particles at the phaco tip can be knocked off from the tip at an undesirable time. The phaco tip must be sufficiently occluded by, or in contact with, the particle in order to effectively remove such particles. In order to circumvent or manage this effect, surgeons typically reduce the voltage amplitude shaping pulse to keep small particles from being knocked off at the tip. This method of reducing the voltage amplitude can materially limit cutting effectiveness. In general, blockage of the phaco tip dramatically reduces cutting effectiveness, as does any overall reduction in voltage amplitude applied.
Typical available systems may employ what is known as an occluded mode, wherein an occlusion or blockage of the phaco tip, such as by a piece of lens, is addressed in some manner. The typical way of addressing occlusion has been to cease operation until the tip is no longer occluded, i.e. simply releasing the pressure applied to the tip. This enables the operator/surgeon to manually move the tip and allow the occlusion to disengage from the instrument. Such an implementation simply monitors the pressure of vacuum on the tip, and when it exceeds a certain amount, the vacuum is released or no longer applied.
Increased efficiency in this environment is desirable, such that any devices or procedures that can lessen heat applied to the affected area or simplify the work of the operator surgeon is beneficial. Patient recovery time can be enhanced when desirable performance is provided, such as reduced heat to the affected region.
Based on the foregoing, it would be advantageous to provide a system that employs a wave pulse shaping mechanism that enables successful surgeries without delivering excessive heat to the surgical site, and allows operators to operate the phacoemulsification system effectively under both occluded and non-occluded conditions. It would also be beneficial to overcome the aforementioned drawbacks present in previously known ultrasonic tissue removal systems.
According to one aspect of the present design, there is provided a method of delivering ultrasonic energy during a surgical procedure, such as a phacoemulsification procedure. The method comprises applying at least one pulse, and typically multiple pulses, each having a pulse shape. The pulse shape comprises a predetermined pulse shape portion and either an increased energy portion comprising an increase in energy proportional to an increase in sensed aspiration vacuum pressure or a decreased energy portion comprising a decrease in energy proportional to a decrease in sensed aspiration vacuum pressure.
According to a second aspect of the present design, there is provided an apparatus comprising a device configured to encounter vacuum pressure at the surgical area, a vacuum sensor configured to monitor vacuum pressure encountered by the device, and a computer configured to compute an ultrasonic pulse profile for delivery to a needle configured to vibrate based on the ultrasonic pulse profile received, the ultrasonic pulse profile based on monitored vacuum pressure received from the vacuum sensor. The ultrasonic pulse profile comprises a baseline ultrasonic pulse region and an altered ultrasonic pulse region, the altered ultrasonic pulse region comprising a pulse portion altered based on monitored vacuum pressure.
These and other advantages of the present invention will become apparent to those skilled in the art from the following detailed description of the invention and the accompanying drawings.
The present invention is illustrated by way of example, and not by way of limitation, in the figures of the accompanying drawings in which:
The following description and the drawings illustrate specific embodiments to enable those skilled in the art to practice the system and method described. Other embodiments may incorporate structural, logical, process and other changes. Examples merely typify possible variations. Individual components and functions are generally optional unless explicitly required, and the sequence of operations may vary. Portions and features of some embodiments may be included in or substituted for those of others.
Currently available phacoemulsification systems include a variable speed peristaltic pump, a vacuum sensor, an adjustable source of ultrasonic power, and a programmable microprocessor with operator-selected presets for controlling aspiration rate, vacuum and ultrasonic power levels. A phacoemulsification handpiece is interconnected with a control console by an electric cable for powering and controlling the piezoelectric transducer. Tubing provides irrigation fluid to the eye and enables withdrawal of aspiration fluid from an eye through the handpiece. The hollow needle of the handpiece may typically be driven or excited along its longitudinal axis by the piezoelectric effect in crystals created by an AC voltage applied thereto. The motion of the driven crystal is amplified by a mechanically resonant system within the handpiece such that the motion of the needle connected thereto is directly dependent upon the frequency at which the crystal is driven, with a maximum motion occurring at a resonant frequency. The resonant frequency is dependent in part upon the mass of the needle interconnected therewith, which is typically vibrated by the crystal.
One similar system and design is illustrated in U.S. patent application Ser. No. 10/387,335, entitled “Modulated Pulsed Ultrasonic Power Delivery System and Method,” inventors Kenneth E. Kadziauskas et al., filed Mar. 12, 2003, the entirety of which is incorporated herein by reference.
Power control of the phacoemulsification handpiece is highly critical to successful phacoemulsification surgery. Certain previous systems address the requirements of power control for a phacoemulsification handpiece based on the phase angle between the voltage applied to a handpiece piezoelectric transducer and the current drawn by the piezoelectric transducer and/or the amplitude of power pulses provided to the handpiece. The typical arrangement is tuned for the particular handpiece, and power is applied in a continuous fashion or series of solid bursts subject to the control of the surgeon/operator. In certain circumstances, the surgeon/operator may wish to apply these power bursts for a duration of time, cease application of power, then reapply at this or another power setting. The frequency and duration of the burst is typically controllable, as is the length of the stream of bursts applied to the affected area. The time period where power is not applied enables cavitation in the affected area, and broken lens sections may be removed using aspiration provided by the handpiece or an aspiration apparatus. The on/off application of power facilitates breaking the cataract into pieces and relatively efficient removal thereof.
The present design provides a system and method for precisely controlling the movement of the phacoemulsification needle tip using a pulse shape controlled, or partially based on, sensed vacuum pressure. Controlling particle movement at the needle tip may enable better destruction (i.e. emulsification) of large and small particles. The present vacuum based design determines whether additional energy is required to bump or move a large particle away from the needle tip. The system may determine less energy is needed to enable a smaller particle to be drawn to the needle tip. The present design can include a control loop to sense and continuously monitor actual vacuum at the needle tip, and the design may vary the amount of ultrasonic power delivered to the surgical area in response to the observed actual needle tip vacuum. Moreover, the present design may actively vary the amount of ultrasonic power delivered based on the size of the particle, directly proportional to measured vacuum.
The block representation of the handpiece 104 includes a needle and electrical means, typically a piezoelectric crystal, for ultrasonically vibrating the needle. The control unit 105 supplies power on line 102 to a phacoemulsification handpiece/needle 104. An irrigation fluid source is fluidly coupled to handpiece/needle 104 (not shown in
The control unit 105 may include a manual user interface 120 to allow the surgeon/operator to preset various system parameters. User defined system parameters may include, but are not limited to, selecting pulse shape amplitude mode, setting maximum vacuum, minimum pulse shape amplitude, and maximum pulse shape amplitude. In addition, the computer 109 may provide operator-lettable limits for aspiration rates, vacuum levels and ultrasonic power levels. The surgeon/operator may select the pulse shape amplitude (PSA) mode during any phase of an operational procedure via the manual user interface 120 console. Selection of PSA mode may direct the microprocessor computer 109 to continuously monitor the resultant vacuum at line/handpiece needle 108 by measuring the pressure on line 110 via vacuum sensor 113. The computer 109 may respond to a surgeon selected preset maximum vacuum level and preset minimum and maximum PSA values using signals from the vacuum sensor 113. If the received vacuum from vacuum sensor 113 exceeds a maximum vacuum level as set by the surgeon, an occluded condition exists, and the system can halt vacuum pressure in an effort to enable occlusion removal.
Operation of the control unit 105 in response to an occluded-unoccluded condition of handpiece 104 is shown in the flow diagram of
The present design may continuously vary the ultrasonic power delivered to the surgical area in response to particle size as determined by actual vacuum present on the aspiration line 108. Although the present design is described in terms of varying pulse shaping amplitude as a function of vacuum, alternate embodiments of the present design may include varying other system parameters such as phaco power and duty cycle as a function of vacuum, vacuum level, or vacuum pressure. Note that as used herein, the term “vacuum” is intended to mean any type of negative pressure, including a vacuum condition, vacuum level, or vacuum pressure.
As illustrated in
In this manner, the present design may dynamically change the total amount of energy delivered to the surgical area in real-time based on conditions encountered, specifically vacuum pressure received or sensed. The present design may provide a continuous control loop for increasing or decreasing the amount of ultrasonic energy delivered by performing an PSA wave shape function at point 207 based on the combination of the standard wave shape at point 205 modified by the PSA waveform at point 204 in response to measured vacuum. If the surgeon/operator elects to disable the PSA mode at point 201, the phacoemulsification system generates the standard phaco wave shape (e.g. burst, pulsed, etc.) at point 208 and performs the standard phaco wave shape at point 209.
The present design may calculate the pulse shape amplitude based on the following equation:
PSA=MinAmp+[(ActualVac)*(MaxAmp−MinAmp)]/(MaxVac) (1)
where:
MaxAmp=maximum pulse shape amplitude,
MinAmp=minimum pulse shape amplitude,
ActualVac=actual vacuum,
MaxVac=maximum vacuum, and
PSA=pulse shape amplitude.
Equation (1) provides valid pulse shape amplitude values for MaxVac values greater than zero. Table 1 provides resultant PSA values calculated based on an example of an implementation of Equation (1) using the following values:
MaxVac=200 mm/hg;
MinAmp=10%; and
MaxAmp=40%, where the percentage value represents percent above unmodified signal amplitude. 10% represents 10 percent above existing or nominal amplitude, or 110% of nominal.
PSA is calculated as a percentage of the nominal wave amplitude generated by the phaco system.
The vacuum level at point 305 may represent a decrease in vacuum as the large particle is bumped or moved away from the phaco needle tip. Movement may result in a decrease in observed vacuum present of the aspiration line. The vacuum level at point 306 is representative of a large particle being precisely held away from the tip to ensure the most efficient destruction or emulsification of the large particle. The present design may generate the pulse shape amplitude waveform represented in Graph C in
Based on the PSA equation, the present design may generate the pulse shape amplitude waveform with an ultrasonic on time at point 310 and off time at point 311. This generated PSA waveform amplitude is 10 percent greater than the standard wave shape shown in Graph A in accordance with a measured vacuum of 0 mm/hg. As vacuum pressure increases from 0 mm/hg to 200 mm/hg, the present design may generate the PSA waveforms shown at points 312, 313, 314 and 315. The PSA waveform increases proportionally to actual vacuum until the MaxVac value is reached.
In this example, the present design may generate a PSA waveform with amplitude 40 percent greater than the standard phaco wave shape shown in Graph A. The actual vacuum at point 304 may represent an occluded phaco needle tip. As the phaco power is increased via the PSA waveform augmentation to the standard or nominal waveform, the large particle may begin to move away from the needle and thus cause a drop in vacuum at point 305. As the large particle moves away from the Phaco needle tip, the needle tip may hold the large particle at a distance from the needle tip, enhancing emulsification of the particle. Large particle movement may be controlled or held in the present design by reducing the PSA waveform amplitude at point 316 in accordance with actual vacuum at point 306.
The amplitude of the wave generated may vary, but also the duration of the pulse and the additional amplitude spike may vary depending on circumstances. In general, a fairly short amplitude spike is added to the nominal waveform, where amplitude of the spike is dependent upon the calculation of Equation (1) or some similar vacuum based function.
The ultrasonic power wave shape shown in Graph B of
The present design has been described using an exemplary square wave phacoemulsification burst mode wave shape. As noted, although the description relates to how the present design modifies the amplitude of a standard pulse wave shape, the present design may alternately or additionally modify the width of the PSA waveform. In this arrangement, additional ultrasonic power may be delivered to the surgical area as required.
The illustrations presented in
The present design may modify amplitude and width of the PSA waveform in order to provide the desired ultrasonic power for efficient phacoemulsification of large and small particles.
The present design is not limited to generating square waves in response to the standard generated phaco wave shape. Other similar waveforms may be employed and depend on the environment encountered, including but not limited to phaco conditions, tip size, operating frequency, fluid conditions, and occlusion conditions.
A further aspect of the present design may include varying the time and power levels based on actual vacuum to attain transient cavatation as quickly as possible in the surgical environment without generating significant heat in the region. As may be appreciated by those skilled in the art, sufficient power is delivered based on the circumstances presented to induce transient cavatation, typically by delivering an initial higher power surge or burst of energy, followed by a drop off in energy from the initial surge in accordance with the present design.
Thus the present design delivers ultrasonic energy during a surgical procedure, such as a phacoemulsification procedure, and comprises applying at least one pulse and typically multiple pulses each having a pulse shape. The pulse shape comprises a predetermined pulse shape portion and either an increased energy portion comprising an increase in energy proportional to an increase in sensed aspiration vacuum pressure or a decreased energy portion comprising a decrease in energy proportional to a decrease in sensed aspiration vacuum pressure. Alternately, the design monitors actual vacuum pressure level at the surgical region, dynamically calculates a pulse shape amplitude (PSA) level based on monitored actual vacuum pressure level, generates a PSA waveform based on the dynamically calculating, and sums a predetermined wave shape with the PSA waveform to produce a PSA wave shape. The design then delivers the PSA wave shape to a handpiece.
The design may be embodied in an apparatus comprising a device configured to encounter vacuum pressure at the surgical area, a vacuum sensor configured to monitor vacuum pressure encountered by the device, and a computer configured to compute an ultrasonic pulse profile for delivery to a needle configured to vibrate based on the ultrasonic pulse profile received, the ultrasonic pulse profile based on monitored vacuum pressure received from the vacuum sensor. The ultrasonic pulse profile comprises a baseline ultrasonic pulse region and an altered ultrasonic pulse region, the altered ultrasonic pulse region comprising a pulse portion altered based on monitored vacuum pressure.
As may be appreciated by those skilled in the art, the present design may be realized in software executing in microprocessor computer 109, or may be implemented with dedicated microcontrollers or analog circuitry.
The foregoing is not determinative or exclusive or L inclusive of all components, interfaces, communications, and operational modes employable within the present design. The design presented herein and the specific aspects illustrated are meant not to be limiting, but may include alternate components while still incorporating the teachings and benefits of the invention, namely a method of generating a pulse shape amplitude in an arrangement that modifies phaco ultrasonic power delivered proportional to actual vacuum present. While the invention has thus been described in connection with specific embodiments thereof, it will be understood that the invention is capable of further modifications. This application is intended to cover any variations, uses or adaptations of the invention following, in general, the principles of the invention, and including such departures from the present disclosure as come within known and customary practice within the art to which the invention pertains.
This application is a continuation application of and claims priority to U.S. application Ser. No. 11/461,741 filed on Aug. 1, 2006, which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2434480 | Anderson | Jan 1948 | A |
3857387 | Shock | Dec 1974 | A |
3941122 | Jones | Mar 1976 | A |
4184510 | Murry et al. | Jan 1980 | A |
4343111 | Inoue | Aug 1982 | A |
4736130 | Puskas | Apr 1988 | A |
4808948 | Patel et al. | Feb 1989 | A |
4827911 | Broadwin et al. | May 1989 | A |
4952834 | Okada | Aug 1990 | A |
4954960 | Lo et al. | Sep 1990 | A |
4970656 | Lo et al. | Nov 1990 | A |
4983901 | Lehmer | Jan 1991 | A |
5001649 | Lo et al. | Mar 1991 | A |
5091656 | Gahn | Feb 1992 | A |
5209221 | Riedlinger | May 1993 | A |
5213569 | Davis | May 1993 | A |
5242404 | Conley et al. | Sep 1993 | A |
5249121 | Baum et al. | Sep 1993 | A |
5268624 | Zanger | Dec 1993 | A |
5279547 | Costin | Jan 1994 | A |
5318563 | Malis et al. | Jun 1994 | A |
5331951 | Kepley | Jul 1994 | A |
5342293 | Zanger | Aug 1994 | A |
5370602 | Kepley | Dec 1994 | A |
5388569 | Kepley | Feb 1995 | A |
5403307 | Zelman | Apr 1995 | A |
5405614 | D'Angelo et al. | Apr 1995 | A |
5406503 | Williams, Jr. et al. | Apr 1995 | A |
5417246 | Perkins et al. | May 1995 | A |
5431664 | Ureche et al. | Jul 1995 | A |
5453087 | Malinowski | Sep 1995 | A |
5520633 | Costin | May 1996 | A |
5534741 | Smith | Jul 1996 | A |
5547459 | Kaufman et al. | Aug 1996 | A |
5582578 | Zhong et al. | Dec 1996 | A |
5591127 | Barwick, Jr. et al. | Jan 1997 | A |
5700240 | Barwick et al. | Dec 1997 | A |
5733256 | Costin | Mar 1998 | A |
5738677 | Colvard et al. | Apr 1998 | A |
5766146 | Barwick, Jr. | Jun 1998 | A |
5797494 | Balling et al. | Aug 1998 | A |
5800365 | Zhong et al. | Sep 1998 | A |
5808396 | Boukhny | Sep 1998 | A |
5836959 | Seibel et al. | Nov 1998 | A |
5852794 | Staggs | Dec 1998 | A |
5873885 | Weidenbenner | Feb 1999 | A |
5938677 | Boukhny et al. | Aug 1999 | A |
5979494 | Perkins et al. | Nov 1999 | A |
5984882 | Rosenschein et al. | Nov 1999 | A |
5997528 | Bisch et al. | Dec 1999 | A |
6010496 | Appelbaum et al. | Jan 2000 | A |
6083193 | Kadziauskas et al. | Jul 2000 | A |
6086598 | Appelbaum et al. | Jul 2000 | A |
6117126 | Appelbaum et al. | Sep 2000 | A |
6155975 | Urich et al. | Dec 2000 | A |
6161545 | Chow | Dec 2000 | A |
6175180 | Angelini et al. | Jan 2001 | B1 |
6193683 | Ludin et al. | Feb 2001 | B1 |
6203516 | Kepley | Mar 2001 | B1 |
6251113 | Appelbaum et al. | Jun 2001 | B1 |
6261297 | Kadziauskas et al. | Jul 2001 | B1 |
6319220 | Bylsma | Nov 2001 | B1 |
6391020 | Kurtz et al. | May 2002 | B1 |
6391042 | Cimino | May 2002 | B1 |
6394974 | Kadziauskas et al. | May 2002 | B1 |
6425883 | Urich et al. | Jul 2002 | B1 |
6428531 | Visuri et al. | Aug 2002 | B1 |
6443900 | Adachi et al. | Sep 2002 | B2 |
6452120 | Chen | Sep 2002 | B1 |
6452123 | Chen | Sep 2002 | B1 |
6452883 | Chan | Sep 2002 | B2 |
6487447 | Weimann et al. | Nov 2002 | B1 |
6506176 | Mittelstein et al. | Jan 2003 | B1 |
6589204 | Sussman et al. | Jul 2003 | B1 |
6610052 | Furumoto | Aug 2003 | B2 |
6629948 | Rockley et al. | Oct 2003 | B2 |
6699212 | Kadziauskas et al. | Mar 2004 | B1 |
6726679 | Dick et al. | Apr 2004 | B1 |
6733491 | Kadziauskas et al. | May 2004 | B2 |
6780165 | Kadziauskas et al. | Aug 2004 | B2 |
6808396 | Kawaguchi et al. | Oct 2004 | B2 |
6884252 | Urich et al. | Apr 2005 | B1 |
6890332 | Truckai et al. | May 2005 | B2 |
6896674 | Woloszko et al. | May 2005 | B1 |
6908472 | Wiener et al. | Jun 2005 | B2 |
6939317 | Zacharias | Sep 2005 | B2 |
6962583 | Kadziauskas et al. | Nov 2005 | B2 |
7077820 | Kadziauskas et al. | Jul 2006 | B1 |
7169123 | Kadziauskas et al. | Jan 2007 | B2 |
7193521 | Moberg et al. | Mar 2007 | B2 |
7316664 | Kadziauskas et al. | Jan 2008 | B2 |
7485106 | Kadziauskas et al. | Feb 2009 | B2 |
20010003155 | Rockley et al. | Jun 2001 | A1 |
20010003295 | Langlotz et al. | Jun 2001 | A1 |
20010003385 | Ise | Jun 2001 | A1 |
20020052600 | Davison et al. | May 2002 | A1 |
20020072741 | Sliwa et al. | Jun 2002 | A1 |
20020082793 | Kadziauskas et al. | Jun 2002 | A1 |
20040092921 | Kadziauskas et al. | May 2004 | A1 |
20040092922 | Kadziauskas et al. | May 2004 | A1 |
20040193182 | Yaguchi et al. | Sep 2004 | A1 |
20050054971 | Steen et al. | Mar 2005 | A1 |
20050209560 | Boukhny et al. | Sep 2005 | A1 |
20050209621 | Gordon et al. | Sep 2005 | A1 |
20050288665 | Woloszko | Dec 2005 | A1 |
20060149301 | Claus | Jul 2006 | A1 |
20060195077 | Kadziauskas et al. | Aug 2006 | A1 |
20060264809 | Hansmann et al. | Nov 2006 | A1 |
20070056596 | Fanney et al. | Mar 2007 | A1 |
20070073214 | Dacquay et al. | Mar 2007 | A1 |
20070078379 | Boukhny et al. | Apr 2007 | A1 |
Number | Date | Country |
---|---|---|
19940712 | Mar 2001 | DE |
270819 | Jun 1988 | EP |
270819 | Jan 1989 | EP |
336620 | Oct 1989 | EP |
336620 | Dec 1993 | EP |
1351631 | Oct 2003 | EP |
1537840 | Jun 2005 | EP |
2204337 | Aug 1990 | JP |
5038343 | Feb 1993 | JP |
6183762 | Jul 1994 | JP |
6189972 | Jul 1994 | JP |
9313496 | Dec 1997 | JP |
2001161740 | Jun 2001 | JP |
2002087836 | Mar 2002 | JP |
2002233534 | Aug 2002 | JP |
WO-9520374 | Aug 1995 | WO |
WO-9808442 | Mar 1998 | WO |
WO-0051508 | Sep 2000 | WO |
WO-0064388 | Nov 2000 | WO |
WO0113838 | Mar 2001 | WO |
WO-02056806 | Jul 2002 | WO |
WO-2005092023 | Oct 2005 | WO |
Number | Date | Country | |
---|---|---|---|
20100114009 A1 | May 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11461741 | Aug 2006 | US |
Child | 12684657 | US |